Suppr超能文献

肝素治疗期间急性深静脉血栓形成患者的蛋白C抑制剂及蛋白C途径的其他成分

Protein C inhibitor and other components of the protein C pathway in patients with acute deep vein thrombosis during heparin treatment.

作者信息

Tabernero D, España F, Vicente V, Estellés A, Gilabert J, Aznar J

机构信息

Department of Hematology, Hospital General, Salamanca, Spain.

出版信息

Thromb Haemost. 1990 Jun 28;63(3):380-2.

PMID:2169656
Abstract

The protein C inhibitor (PCI) concentration and other parameters of the protein C pathway were studied in 19 patients with symptomatic acute deep vein thrombosis before and during the first 5 days of heparin treatment. The mean levels of PCI antigen and activity decreased rapidly and significantly during the first day of heparin therapy from 83 and 84% to 60 and 59% of the pooled normal human plasma (p less than 0.01), respectively, and to 56 and 54% after 5 days of treatment (p less than 0.01). In contrast, antithrombin III decreased progressively 25% during 5 days of heparin treatment. Protein C antigen and activity and total protein S remained unchanged during heparin treatment. Free protein S was decreased before heparin treatment (83%, p less than 0.05) and increased to normal values after 5 days of treatment. C4b-binding protein was significantly increased before and during heparin treatment (p less than 0.01). Activated protein C (APC) complexed to its two major plasma inhibitors, PCI and alpha 1-antitrypsin (alpha 1AT) were measured by specific ELISA's. Before treatment, 18 of the 19 patients studied had increased levels of APC:alpha 1AT complexes with a mean value of 27 +/- 22 ng/ml (range, 6-86 ng/ml) compared to normal values (8 +/- 2 ng/ml) and 12 of the patients also had detectable APC:PCI complex levels with a mean value of 11 +/- 17 ng/ml (range, 5-68 ng/ml). Both APC:inhibitor complexes decreased significantly during heparin treatment.

摘要

对19例有症状的急性深静脉血栓形成患者在肝素治疗前及治疗的前5天期间,研究了蛋白C抑制剂(PCI)浓度及蛋白C途径的其他参数。肝素治疗第1天,PCI抗原和活性的平均水平迅速且显著下降,分别从正常混合人血浆的83%和84%降至60%和59%(p<0.01),治疗5天后降至56%和54%(p<0.01)。相比之下,抗凝血酶III在肝素治疗5天期间逐渐下降了25%。肝素治疗期间,蛋白C抗原和活性以及总蛋白S保持不变。游离蛋白S在肝素治疗前降低(83%,p<0.05),治疗5天后升至正常水平。C4b结合蛋白在肝素治疗前及治疗期间显著升高(p<0.01)。通过特异性酶联免疫吸附测定法检测与两种主要血浆抑制剂PCI和α1-抗胰蛋白酶(α1AT)结合的活化蛋白C(APC)。治疗前,在研究的19例患者中,18例患者的APC:α1AT复合物水平升高,平均值为27±22 ng/ml(范围6 - 86 ng/ml),而正常水平为(8±2 ng/ml),12例患者还可检测到APC:PCI复合物水平,平均值为11±17 ng/ml(范围5 - 68 ng/ml)。肝素治疗期间,两种APC:抑制剂复合物均显著降低。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验